Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
February 8, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 4, 2026 - … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and …
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
January 28, 2026 - … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and …
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
January 25, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
January 12, 2026 - … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … arrangements; the potential of our commercial business and pipeline programs, including nusinersen; and risks and …
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
January 5, 2026 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 22, 2025 - … study in pre-symptomatic SOD1 -ALS and a robust discovery pipeline in ALS CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE … In addition to QALSODY, the company has a robust discovery pipeline including efforts to address TDP43 pathology for the … of ALS; the potential of our commercial business and pipeline programs, including QALSODY; and risks and …
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 8, 2025 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 5, 2025 - … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and …
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 3, 2025 - … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and … growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product … Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and …
